Clinical Trials for Gynecologic Cancers
4 Open Trials
| Trial Type & Disease | Protocol No. & Open Date | Summary |
|---|---|---|
| Therapeutic Uterine | VICCGYN1174 09/26/2012 | A Phase II, Open-Label, Single-Arm, Non-Randomized, Multi-Center Study to Evaluate the Efficacy of Oral TKI258 as Second-Line Therapy in Patients with Either FGFR2 Mutated or Wild-Type Advanced and/or Metastatic Endometrial Cancer |
| Therapeutic Gynecologic; Ovarian | VICCGYN1206 09/25/2012 | A phase II randomized open label study of MM-121 in combination with paclitaxel versus paclitaxel alone in patients with platinum resistant/refractory advanced ovarian cancers |
| Therapeutic Adrenocortical; Bladder; Breast; Cervical; Colon; Dermatologic; Esophageal; GIST; Gastric/Gastroesophageal; Gynecologic; Head/Neck; Kidney (Renal Cell); Liver; Lung; Multiple Myeloma; Neuroendocrine; Ovarian; Pancreatic; Prostate; Rectal; Sarcoma; Small Cell; Uterine | VICCMD1188 06/08/2012 | An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers |
| Screen, Detect, Diagnose Adrenocortical; Bladder; Breast; Cervical; Colon; Dermatologic; Esophageal; GIST; Gastric/Gastroesophageal; Gynecologic; Head/Neck; Kidney (Renal Cell); Liver; Lung; Multiple Myeloma; Neuroendocrine; Ovarian; Pancreatic; Prostate; Rectal; Sarcoma; Small Cell; Uterine | VICCMD1286 12/17/2012 | Screening Protocol to Detect BRAF V600 Mutation Positive Patients for Enrollment into Clinical Research Studies of Vemurafenib |
You do not have JavaScript enabled. This site works better with JavaScript turned on.
